Head of Business Development
Dr. Alex Harding
Dr. Alex Harding serves as Senior Vice President and Head of Business Development. He brings extensive leadership experience in biopharma business development and corporate strategy to CRISPR Therapeutics. Most recently, Dr. Harding served as Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics, a biotechnology company developing small molecule therapies to modulate RNA processing. At Remix, Dr. Harding co-founded the company, sourced technology, helped set the strategic direction, and led financing efforts, raising over $150M from a top-tier investor syndicate (Seed, Series A, Series B). He also led business development processes, resulting in a collaboration with Janssen Pharmaceuticals. Before Remix, Dr. Harding was a Senior Associate at Atlas Venture, where he helped to start new biotech companies, including Triplet Therapeutics, Vedere Bio, Third Harmonic Bio, and Remix Therapeutics. Dr. Harding received an M.D. from Johns Hopkins School of Medicine, with honors, and completed his residency in internal medicine at Massachusetts General Hospital. Additionally, Dr. Harding received an M.B.A. from Harvard Business School and a B.A. from Yale University. Dr. Harding also continues to practice medicine at a community health center in Chelsea, Massachusetts.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.